J&J Reveling In RAVEL Drug-Coated Stent Data: No Restenosis At Six Months
This article was originally published in The Gray Sheet
Executive Summary
Johnson and Johnson/Cordis' European RAVEL study data sets a high standard for other drug-coated stent developers, including no restenosis at six-month follow-up.